Completed PHASE2 INTERVENTIONAL 3-arm NCT00556894

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis

Sponsor: Can-Fite BioPharma

Conditions Rheumatoid Arthritis

Interventions CF101 Placebo

Updated 8 times since 2017 Last updated: Feb 27, 2018 Started: Feb 29, 2008 Primary completion: Mar 31, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Can-Fite BioPharma and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Apr 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Can-Fite BioPharma

Data source: Can-Fite BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Ashkelon, Israel , Belgrade, Serbia , Donetsk, Ukraine , Elblag, Poland , Haifa, Israel , Hradec Králové, Czechia , Jerusalem, Israel , Kfar Saba, Israel , Kiev, Ukraine and 12 more locations